文献速递其他结缔组织病

利妥昔单抗治疗快速进展性幼年系统性硬化症

Rituximab for rapidly progressive juvenile systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本文报告4例快速进展性幼年系统性硬化症(JSSc)患者,接受利妥昔单抗(RTX)联合低剂量泼尼松和吗替麦考酚酯(MMF)治疗至少1年。治疗后所有患者J4S评分、雷诺现象和皮肤受累均显著改善,心脏和肺功能参数亦有改善,未报告重大副作用。提示RTX联合MMF可有效阻止JSSc快速进展。

要点

  • 4例快速进展性JSSc患者接受RTX联合MMF治疗1年后J4S、雷诺现象及皮肤受累均显著改善。
  • 3例以心脏受累为主者中2例心肌功能改善(EF分别+37%和+19%),1例心律失常消失。
  • 1例严重肺受累者呼吸功能显著改善(FVC +46%,FEV1 +33%,DLCO +30%)。

核心结论

  • RTX联合MMF可有效阻止快速进展性JSSc的快速进展。

研究设计与样本

  • 病例系列研究,纳入4例接受RTX治疗至少1年的快速进展性JSSc患者。
  • 所有患者接受每年4个疗程静脉RTX 375 mg/m2(第0天和第14天给药,每3个月间隔),同时口服低剂量泼尼松和MMF。
  • 基线和每6个月记录肺和心肌功能参数、肌肉、血管和皮肤改变,并以幼年系统性硬化症严重度评分(J4S)评估总体疾病严重度。

主要发现

  • 4例患者(3男1女),年龄8-17岁,其中3例以心脏受累为主,1例为严重肺受累。
  • RTX治疗1年后所有患者J4S、雷诺现象和皮肤受累均显著改善。
  • 以心脏受累为主者中2例心肌功能改善(左心室射血分数分别+37%和+19%),第3例心律失常消失。
  • 严重肺受累者呼吸功能显著改善(用力肺活量+46%,第1秒用力呼气容积+33%,一氧化碳弥散量+30%)。
  • 未报告重大副作用。

临床怎么用

  • 对快速进展性JSSc患者,可考虑RTX联合MMF及低剂量泼尼松方案以阻止疾病快速进展。

局限性

  • 样本量小(4例),为病例系列研究,缺乏对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Juvenile systemic sclerosis (JSSc) with rapidly progressive course is a life-threatening condition associated with a poor prognosis. Recently, rituximab (RTX) has been shown to be a promising treatment for adult patients with SSc. We present a series of four patients with rapidly progressive JSSc successfully treated with RTX. METHODS: Clinical, laboratory and functional parameters were collected from four patients with rapidly progressive JSSc treated with RTX for at least 1 year. All patients underwent four yearly courses of i.v. RTX 375 mg/m2 on day 0 and 14, at 3-month intervals. Low dose oral prednisone and MMF were also administered. Data were recorded at baseline and every 6 months and included pulmonary and myocardial function parameters, muscular, vascular and skin changes. The Juvenile Systemic Sclerosis Severity Score (J4S) estimated the overall disease severity over time. RESULTS: Four patients (three males, one female), aged 8-17 years, entered the study. Three patients presented with prevalent cardiac involvement, one with severe pulmonary involvement. After 1 year of RTX treatment, all patients showed significant improvement of J4S, Raynaud's phenomenon and cutaneous involvement. Among those with prevalent cardiac involvement, two showed an improvement of the myocardial function (left ventricular ejection fraction [EF] +37% and +19%, respectively) and in the third arrhythmias disappeared. The patient with severe pulmonary involvement showed a significant improvement of the respiratory function (forced vital capacity +46%, forced expiratory volume in 1 s +33%, diffusing capacity of the lung for carbon monoxide [DLCO] +30%). No major side effects were reported. CONCLUSIONS: Our data suggest that a combination of RTX and MMF is effective in arresting the rapid progression of JSSc.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zulian F, Dal Pozzolo R, Meneghel A, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 32442284. doi:10.1093/rheumatology/keaa193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。